Pfizer Limited (PFIZER.NS)
- Previous Close
4,413.20 - Open
4,448.00 - Bid 4,460.40 x --
- Ask 4,464.00 x --
- Day's Range
4,405.00 - 4,488.00 - 52 Week Range
3,701.00 - 6,451.15 - Volume
9,163 - Avg. Volume
47,288 - Market Cap (intraday)
204.048B - Beta (5Y Monthly) 0.08
- PE Ratio (TTM)
33.14 - EPS (TTM)
134.60 - Earnings Date May 19, 2025
- Forward Dividend & Yield 35.00 (0.79%)
- Ex-Dividend Date Aug 21, 2024
- 1y Target Est
5,971.67
Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers internal medicine and anti-infectives services to hospitals and nursing homes. It serves healthcare providers, government and private hospitals, and retail pharmacies. The company sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.
www.pfizerltd.co.in1,721
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: PFIZER.NS
View MorePerformance Overview: PFIZER.NS
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PFIZER.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PFIZER.NS
View MoreValuation Measures
Market Cap
201.89B
Enterprise Value
179.60B
Trailing P/E
32.80
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.03
Price/Book (mrq)
5.38
Enterprise Value/Revenue
8.03
Enterprise Value/EBITDA
19.95
Financial Highlights
Profitability and Income Statement
Profit Margin
27.53%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
22.36B
Net Income Avi to Common (ttm)
6.16B
Diluted EPS (ttm)
134.60
Balance Sheet and Cash Flow
Total Cash (mrq)
22.81B
Total Debt/Equity (mrq)
1.99%
Levered Free Cash Flow (ttm)
--